Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
Relapsing-remitting Multiple SclerosisActive Secondary Progressive Multiple SclerosisThis study is an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
A Study for Patients With Multiple Sclerosis
Secondary Progressive Multiple SclerosisTo obtain additional safety data in subjects who have previously completed the MBP8298-01 study "A Double Blind Placebo Controlled Multi-Centre to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Multiple Sclerosis" Dirucotide is generic name for MBP8298.
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Active Secondary Progressive Multiple SclerosisThis is an observational, multicenter, single-arm, prospective study conducted in Italy
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants...
Secondary Progressive Multiple SclerosisThis is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2). Part 1: The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objectives of Part 1 of this study are to determine the proportion of participants with consistent improvement in Timed 25-Foot Walk (T25FW), the change in participant-reported ambulatory status as measured by the 12-item MS Walking Scale (MSWS-12), the change in manual ability based on the ABILHAND Questionnaire, the impact of natalizumab on participant-reported quality of life using the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical), the change in whole brain volume between the end of study and Week 24 using magnetic resonance imaging (MRI) and the proportion of participants experiencing progression of disability as measured by individual physical Expanded Disability Status Scale (EDSS) system scores. Part 2: The primary objective of Part 2 of the study is to evaluate the safety profile of natalizumab in participants with SPMS. The secondary objectives of Part 2 of the study are to investigate long-term disability (based on clinical or participant-reported assessments) in participants with SPMS receiving natalizumab treatment for approximately 4 years and to assess change in brain volume and T2 lesion volume.
Study Evaluating Mitoxantrone in Multiple Sclerosis
Secondary Progressive Multiple SclerosisThe purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients.
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus...
Multiple SclerosisPathologic Processes6 moreThe investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Primary Progressive Multiple SclerosisThe goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized...
Primary Progressive Multiple SclerosisThe purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS. This was an open-label, single-arm extension study to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study. The core study completed and eligible patients enrolled into the extension study at the next scheduled or unscheduled core study visit. All patients, regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension study. The extension study was terminated early after the results of the core study became available showing that the study did not meet its primary endpoint which was defined as confirmed disability progression in this population
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Relapsing Remitting Multiple SclerosisSecondary-progressive Multiple Sclerosis2 moreNoninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments to enhance their cognitive aptitudes.
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
Multiple SclerosisClinically Isolated Syndrome2 moreThis project aims to analyze ocular motility problems, visual processing speed and microperimetry, and their relationship with consolidated retinal structural biomarkers (optical coherence tomography, OCT) in patients with Multiple Sclerosis w/w reading complaints comparing with healthy subjects.